Canada markets closed

Generation Bio Co. (GBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3000-0.3700 (-7.92%)
At close: 04:00PM EDT
4.3300 +0.03 (+0.70%)
After hours: 06:13PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.6700
Bid4.2900 x 1800
Ask4.3100 x 800
Day's Range4.2700 - 4.8160
52 Week Range3.4000 - 9.5900
Avg. Volume493,029
Market Cap286.464M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-2.1800
Earnings DateMay 03, 2023 - May 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.33
  • Zacks

    Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio

    Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.

  • Reuters

    UPDATE 2-Moderna signs licensing deal with Generation Bio in push beyond COVID

    Moderna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots. Generation Bio's shares rose about 13.14% to $4.40 in premarket trading on Thursday. Moderna will pay $40 million in cash upfront, and make a $36 million equity investment in Cambridge, Massachusetts-based Generation Bio.

  • GlobeNewswire

    Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

    Collaboration will extend the applications of each company’s platform through discovery and development of novel lipid nanoparticles using Generation Bio’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system Moderna has acquired an option to license Generation Bio’s ctLNP and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver program Moderna will fund all research and develop